[European Organization for Research and Treatment of Cancer QLQ-C30 and functional assessment of cancer therapy- general for measurement of quality of life in colorectal cancer patients who received adjuvant chemotherapy- a comparison].
Quality of life (QOL) was measured prospectively using the European Organization for Research and Treatment of Cancer QLQ-C30 (QLQ-C30) and Functional Assessment of Cancer Therapy-General (FACT-G) in 94 colorectal cancer patients who received adjuvant chemotherapy with oral uracil/tegafur plus leucovorin. Two QOL questionnaires were then compared with reference to corresponding scales. The post-treatment assessments changed significantly from the baseline values and favored post-treatment for all scales except social well-being of the FACT-G. All scales except social well-being in patients with Grade 0-1 toxicities were better than those with Grade 2-3 toxicities. Social well-being in patients with Grade 2-3 toxicities were worse than those with Grade 0-1. When corresponding scales between the two QOL questionnaires were compared, a high correlation for physical domain or emotional domain was found, whereas no correlation was noticed for social domain. In conclusion, the social domain of the two QOL questionnaires may evaluate different aspects of QOL.
Tsunoda
Akira
A
Dept. of Surgery, Kameda General Hospital, Japan.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000523:psychology*; D005060:Europe; D005260:Female; D006801:Humans; D007564:Japan; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011795:Surveys and Questionnaires; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D005641:Tegafur; D014498:Uracil; D002955:Leucovorin